antiparkinsons
TRANSCRIPT
![Page 1: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/1.jpg)
ANTIPARKINSONIAN
AGENTS
MA. LENY ALDA G. JUSAYAN, MDDEPARTMENT OF PHARMACOLOGY
![Page 2: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/2.jpg)
NEURODEGENERATIVE DISORDERS
![Page 3: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/3.jpg)
HOW DOES THE BODY MOVES?
![Page 4: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/4.jpg)
THE BRAIN CONTROLS MOVEMENT
![Page 5: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/5.jpg)
![Page 6: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/6.jpg)
![Page 7: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/7.jpg)
![Page 8: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/8.jpg)
![Page 9: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/9.jpg)
CASE 1
F.B., 70 year old male, living in a nursing home was noticed to have episodes of crying spells and labile mood. He also had difficulty in initiating sleep and had night time awakenings. Caregivers noticed also progressive slowing down of movement associated with fine tremors of the hands at rest. Few days PTC there were noticeable rigidity & impairment of body movements.
![Page 10: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/10.jpg)
PARKINSONISM
• Paralysis Agitans• “SHAKING
PALSY”• Tremors are present
even at rest• Rigidity &
impairment of voluntary movements
• Postural tremor, intention tremors
![Page 11: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/11.jpg)
The UK Parkinson's Disease Society Brain Bank Criteria For Clinical Diagnosis:
• Bradykinesia plus one of rigidity, tremor, or postural instability
• At least three of rest tremor, progressive symptoms, unilateral onset, early response to levodopa, revodopa-induced dyskinesia
• No identifiable cause for the parkinsonism.
![Page 12: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/12.jpg)
Motor Symptoms: Tremor:
70% of patients suffer resting tremor pill rolling quality
can affect all of the limbs as well as the face, neck, head and jaw.
Rigidity: increased tone or stiffness in the muscles mask-like face and clog-like release of
muscles. Bradykinesia
difficulty initiating and continuing movement.
![Page 13: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/13.jpg)
Postural InstabilityForward flexion of neck, hips, knees and elbows leads to poor balance.
Gait disorders Shuffling, small steps described as festination, reduced arm swing and sudden freezing spells lead to problems walking
Swallowing (dysphagia) and Speech disorders (dysarthria) Handwriting: Micrographia
![Page 14: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/14.jpg)
Nonmotor Symptoms:
• Depression: – 20-90% major depressive episode, reactive
or endogenous
• Dementia: – 20% of patients will become demented
(have impairments of 3 of the following in the presence of clear consciousness: language, memory, visuospatial skills, emotionality, personality and cognition
![Page 15: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/15.jpg)
Sleep disturbances: Problems with sleep fragmentation, sleep initiation, early morning awakening, excessive daytime somnolence and parasomnias.
Sexual dysfunctionAbility to drive a car Ability to gain employmentConstipation
![Page 16: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/16.jpg)
![Page 17: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/17.jpg)
What causes Parkinson’s Disease?• A viral cause:• In 1918 there was an outbreak of
Encephalitis Lethargica and many sufferers developed postencephalitic Parkinsonism.
• A toxic substance: • For instance, the illegal drug MPTP (1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine).
• A genetic cause: • Research by the NHGRI (National Human
Genome Research Institute) suggests that a mutated gene, which codes the alpha synuclein protein located on chromosome 4, has a role in familial parkinsonism.
• Other causes: • Head injuries.• Oxidative stress.• Heavy metal ion exposure from
fillings etc.• It is proposed that these factors
cause the neurone's mechanisms for proteolysis to go awry leading to the formation of the characteristic Lewy bodies seen on autopsy of Parkinson’s patients. The cells then fail to function correctly and ultimately die.
![Page 18: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/18.jpg)
PATHOGENESIS:
• Idiopathic
• Genetic (<50 y/o)
• Exposure to unrecognized neurotoxins
• Oxidation reaction with generation of free radicals
• Reduced level of dopamine in the basal ganglia
![Page 19: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/19.jpg)
MOTOR SYMPTOMS:
POSITIVE SYMPTOMS
• Tremor
• Chorea,
• Athetosis
• Ballismus
NEGATIVE SYMPTOMS
• Bradykinesia• Akinesia• Loss of postural
reflexes.
![Page 20: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/20.jpg)
CHOREA
• Irregular, unpredictable involuntary jerks
• Impaired voluntary activity
• ballismus
![Page 21: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/21.jpg)
TICS
• Sudden coordinated abnormal movements
• Repetitive sniffing
• shoulder shrugging
• face & head movement
![Page 22: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/22.jpg)
ATHETOSIS
• Slow & writhing movements
• Abnormal postures (dystonia)
![Page 23: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/23.jpg)
•Extrapyramidal System: •basal ganglia and their cortical connection •basal ganglia are made up of the:
Caudate Nucleus Putamen (Striatum) Globus Pallidus interna (Gpi) Globus Pallidus externa (Gpe) Subthalamic Nucleus Substantia Nigra Main Outputs: Substantia Nigra Globus pallidus interna Both of which feed to the ventrolateral thalamus
![Page 24: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/24.jpg)
The main Pathological feature of Parkinson’s disease is the loss of the dopaminergic nigrostriatal pathway
Dopaminergic neurons in the substantia nigra that normally inhibit the output of GABAergic cells in the striatum are lost
80% of the Dopamine producing cells must be lost before symptoms begin to show
![Page 25: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/25.jpg)
![Page 26: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/26.jpg)
![Page 27: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/27.jpg)
![Page 28: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/28.jpg)
![Page 29: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/29.jpg)
WHAT CAN BE DONE TO HELP PARKINSON’S SUFFERERS?
![Page 30: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/30.jpg)
GOALS OF TREATMENT:• Pharmacologic
attempt to restore dopaminergic activity with levodopa and dopamine agonists
• Restore normal balance of cholinergic & dopaminergic influences on the basal ganglia
![Page 31: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/31.jpg)
CASE 2
F.B., was brought to the clinic for evaluation , diagnosed to have Parkinson’s disease.
• What is the goal in the management of this case?
• What is the first line drug that can relieve the signs and symptoms of parkinsonism
![Page 32: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/32.jpg)
REMEDIES FOR STEP 1: DOPAMINE REPLACEMENT
![Page 33: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/33.jpg)
LEVODOPA
• (-) -3-(3-4 dihydroxyphenyl) L- alanine• Immediate metabolic precursor of dopamine• Levorotatory stereoisomer of dopamine• D1 receptors stimulate adenylcyclase, located
in the zona compacta of the substantia nigra• D2 receptors inhibit adenylcylase, located
postsynaptically on striatal neurons &presynaptically in the substantia nigra
![Page 34: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/34.jpg)
PHARMACOKINETICS:
• Rapidly absorbed from the SI
• Food delays absorption
• Amino acids in food compete with drug
• Peak plasma concentration: 1-2 hrs
• Plasma t ½ : 1-3 hrs
• HVA, DOPAC (dihydroxyphenylacetic acid) are main metabolites
• 1-3% enters the brain
![Page 35: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/35.jpg)
CLINICAL USE:
• Responsiveness may be lost secondary to disappearance of dopaminergic nigostriatal nerve terminals
• Early use lowers mortality rate• Combined with Carbidopa & Benseraside• Sinemet – dopa preparation containing
levodopa in fixed proportion (1:10 or 1:4)• Sinemet 25/100 TID• 30 -60 minutes before meals
![Page 36: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/36.jpg)
ADVERSE EFFECTS:
• Fluctuations in response
• Misc: mydriasis, blood dyscrasias, hot flushes, gout, brownish discoloration of the urine, abnormal smell, priapism, transient elevations of transaminases & BUN
![Page 37: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/37.jpg)
ADVERSE EFFECTS:• GIT effects: vomiting (CTZ)
–Reduced by carbidopa
–Phenothiazenes are contraindicated
• Cardiovascular: tachycardia, ventricular extrasystoles, atrial fibrillation
![Page 38: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/38.jpg)
• Dyskinesias–Common in patients
receiving carbidopa• Behavioral effects:
–Common in patients receiving levodopa
–controlled by clozapine, olanzapine, resperidone
![Page 39: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/39.jpg)
DRUG INTERACTIONS:• Vitamin B6 enhance
extracerebral metabolism of levodopa
–Prevented by decarboxylase inhibitors
• MAO – A inhibitors
–Hypertensive crisis
![Page 40: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/40.jpg)
CONTRAINDICATIONS:
• Psychoses
• Angle closure glaucoma
• Cardiac dysrhythmia– Less incidence in combination with
carbidopa
• PUD
• Melanoma or suspicious undiagnosed skin lesions
![Page 41: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/41.jpg)
CASE 3
• F.B. Was maintained on low dose of Levodopa and was titrated until given the highest dose where he started to had palpitations and chest pain.
• What is next step in your management?
![Page 42: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/42.jpg)
PERIPHERAL DOPAMINE DECARBOXYLASE INHIBITORS (PDI)
• Carbidopa, Benseraside• Does not penetrate the BBB• Reduce the peripheral metabolism of levodopa• Increase plasma levels of levodopa• Prolongs the plasma half life of levodopa• Increase available amounts of dopa for entry into
the brain• Reduce the daily requirement of levodopa by
75%
![Page 43: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/43.jpg)
![Page 44: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/44.jpg)
CASE 4
• F.B. After 1 year of taking Levodopa develop rigidity and bradykinesia with worsening of the tremors.
• What treatment option should F.B. receive?
![Page 45: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/45.jpg)
DOPAMINE AGONISTS
• Do not require enzymatic conversion for an active metabolite
• No potential toxic metabolites
• Do not compete with other substances for an active transport
• First line in parkinsonism
• End of dose akinesia to levodopa
• On & off phenomenon refractory to levodopa
![Page 46: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/46.jpg)
![Page 47: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/47.jpg)
ERGOT ALKALOIDS:
• BROMOCRIPTINE (Parlodel)
– D2 agonists
– Endocrinologic disorders (hyperprolactinemia)
– Absorbed variably in GIT
– Peak plasma levels: 1-2 hrs
![Page 48: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/48.jpg)
ERGOT ALKALOID:
• PERGOLIDE
– Stimulates both D1 and D2
– More effective than bromocriptine
– Associated with clinical or subclinical valvular heart disease
![Page 49: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/49.jpg)
CLINICAL USE:
BROMOCRIPTINE:– 7.5 mg & 30 mg– 1. 25 mg BID after meals X 2-3
months and increase 2.5 mg q 2 wks
PERGOLIDE:- 3 mg daily
- 0.05 mg starter dose
![Page 50: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/50.jpg)
NON-ERGOT DOPAMINE AGONISTS:PRAMIPEXOLE
Preferential affinity to D3Monotherapy is effectiveNeuroprotective (H scavenger)Enhance neurotrophic activityRapidly absorbedPeak plasma concentration: 2 hrs0.125 mg TID then doubled after 1 wkIncrements of 0.75 mg at weekly
intervals
![Page 51: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/51.jpg)
NON-ERGOT ALKALOIDS:• ROPINIROLE
– Pure D2 receptor agonists– 0.25 mg TID then total daily dose is
increased by 0.75 mg at weekly intervals until the 4th wk & increased by 1.5 mg thereafter
![Page 52: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/52.jpg)
ADVERSE EFFECTS:
• GIT: anorexia, nausea, vomiting, bleeding PUD, reflux esophagitis
• Cardiovascular: postural hypotension, painless digital vasospasm
• Dyskinesias• Mental disturbances• Misc: erythromelalgia
![Page 53: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/53.jpg)
CONTRAINDICATIONS:
• History of psychotic illness
• Recent myocardial infarction
• Peripheral vascular disease
• Peptic ulceration
![Page 54: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/54.jpg)
APOMORPHINE
• Apokyn• Potent dopamine agonist• Temporary relief of off-periods of
akinesia • Rapidly taken by blood and brain (10
minutes) and persists for 2 hours• Nausea – trimethobenzamide• Dyskinesias, drowsiness, sweating,
hypotension, bruising at injection site
![Page 55: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/55.jpg)
MONOAMINE OXIDASE INHIBITORS
MAO – A: metabolizes NE & serotonin
MAO – B: metabolizes dopamine
![Page 56: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/56.jpg)
SELEGILINE (Deprenyl)
• Selective irreversible inhibitor of
MAO-B (normal doses)
• Inhibits MAO-A (higher doses)
• Retards breakdown of dopamine
• Prolongs & enhances the effect of levodopa
• Adjunct in fluctuating response to levodopa
![Page 57: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/57.jpg)
SELEGELINE
• 5 mg with breakfast & lunch
• Cause insomnia when taken later during the day
• Not to be taken with meperidine, TCAs, SSRIs
• Increase adverse effects of levodopa
• METABOLITES: amphetamine & metamphetamine
![Page 58: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/58.jpg)
DRUG INTERACTION:
• Stupor, rigidity, agitation, and hyperthermia - MEPERIDINE
![Page 59: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/59.jpg)
RASAGILINE
• MAO-B inhibitor
• Potent than selegiline in preventing MAO-B toxins induced parkinsonism (MPTP)
• Combination with levodopa – HPN crisis
![Page 60: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/60.jpg)
CATHECO-O-METHYLTRANSFERASE INHIBITORS:
• Compensatory activation pathways of levodopa metabolism after dopa decarboxylase inhibition
• Increase 3-O-methyldopa (3OMD) poor therapeutic response to levodopa– Competes with levodopa for an active carrier
mechanism in the intestinal mucosa & BBB
![Page 61: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/61.jpg)
CATHECOL-O-METHYLTRANSFERASE INHIBITORS: (SELECTIVE)
• TOLCAPONE- central & peripheral metabolism
• ENTACAPONE– peripheral metabolism– Prolongs the duration of levodopa by
decreasing its peripheral metabolism– Helpful in patients receiving levodopa
who have fluctuations– t ½ = 2 hrs
![Page 62: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/62.jpg)
STALEVO
• Combination of levodopa with both carbidopa and entacapone
• Simplifies drug regimen
• Requires consumption of a lesser number of tablets
![Page 63: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/63.jpg)
![Page 64: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/64.jpg)
SIDE EFFECTS:
• Postural hypotension• Fatigue• Somnolence• Peripheral edema• Nausea• Constipation• Dyskinesias• Confusion
![Page 65: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/65.jpg)
AMANTADINE
• Antiviral agent
• Potentiates dopaminergic function by influencing the synthesis, release, reuptake of dopamine
PHARMACOKINETICS:peak plasma concentration: 1-4 hrs
after oral dosePlasma t ½ = 2-4 hrs
![Page 66: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/66.jpg)
![Page 67: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/67.jpg)
CLINICAL USE:
• Less potent than levodopa and benefits are short-lived
• 100 mg BID-TID
ADVERSE REACTIONS:Restlessness, depression, irritability,
insomnia, agitation, excitement, hallucinations & confusion
Livedo reticularis – clears within a month after drug withdrawal
![Page 68: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/68.jpg)
![Page 69: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/69.jpg)
CONTRAINDICATIONS:
• History of seizures
• Heart failure
![Page 70: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/70.jpg)
ACETYLCHOLINE BLOCKING AGENTS:• Improve tremor & rigidity of
parkinsonism but have little effect in bradykinesia
• Benztropine mesylate
• Biperiden
• Orphenadrine
• Procyclidine
• Trihexyphenidyl
![Page 71: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/71.jpg)
ADVERSE EFFECTS:
• CNS
• Mydriasis, urinary retention, constipation, tachycardia, tachypnea, increase IOP, palpitations, cardiac arrythmias
• Acute suppurative parotitis
• Dryness of the mouth
![Page 72: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/72.jpg)
CONTRAINDICATIONS:
• Prostatic hyperplasia
• Obstructive GI diseases
• Angle closure glaucoma
![Page 73: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/73.jpg)
The net result of all of these medications is the balancing out of the acetylcholine/dopamine balance and an improvement in movement
![Page 74: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/74.jpg)
![Page 75: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/75.jpg)
SURGICAL PROCEDURES:
Thalamotomy – conspicous tremor
Posteroventral pallidotomy or deep-brain stimulation
![Page 76: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/76.jpg)
NEURONAL DEATH
EXCITOTOXICITY
• Environmental chemicals may contribute to neurodegenerative disorders
• Can occur with excessive glutamate and kainic acids
• Results from sustained rise in intracellular Ca
![Page 77: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/77.jpg)
NEURONAL DEATH
APOPTOSIS
• Cell is systematically dismantled & shrunken remnants are removed by macrophages without causing inflammation
![Page 78: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/78.jpg)
NEURONAL DEATH
OXIDATIVE STRESS
• Result of excessive production of oxygen and hydroxyl free radicals and hydrogen peroxide
![Page 79: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/79.jpg)
CLINICAL SCENARIO
• A.D. 70 year old female living in a nursing home, has gradual onset of difficulty in recalling what time she has taken her snack but easily recalls the first ball she had in high school.
![Page 80: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/80.jpg)
ALZHEIMER’S DISEASE
• Loss of intellectual ability with age• Dementia that does not have
antecedent cause• Associated with brain shrinkage,
localized loss of neurons in the hippocampus & basal forebrain
• Amyloid plaques, neurofibrillary tangles in the hippocampus
• Loss of cholinergic neurons
![Page 81: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/81.jpg)
![Page 82: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/82.jpg)
MOLECULAR MODEL FOR THE DEVELOPMENT OF ALZHEIMERS DISEASE
![Page 83: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/83.jpg)
PATHOPHYSIOLOGY:
• Decrease in ACETYLCHOLINE• CHOLINERGIC DEFICIENCY
SYNDROME• Decrease in markers of cholinergic
neuron activity• Changes in brain glutamate, dopamine,
norepinephrine, serotonin and somatostatin activity
• Cholinergic and other neurons die or are destroyed
![Page 84: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/84.jpg)
PATHOPHYSIOLOGY:
• Abnormal neuronal lipoprotein processing
• Familial form is associated with abnormal lipoprotein - APOLIPOPROTEIN E4
![Page 85: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/85.jpg)
AMYLOID PLAQUES
• β AMYLOID PROTEIN – by product of neuronal death
![Page 86: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/86.jpg)
NEUROFIBRILLARY TANGLES:
• More abundant in AD
• tangles = severity of cognitive impairment
![Page 87: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/87.jpg)
![Page 88: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/88.jpg)
DRUGS FOR ALZHEIMER’S DISEASE
![Page 89: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/89.jpg)
CHOLINESTERASE INHIBITOR:
![Page 90: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/90.jpg)
CHOLINESTERASE INHIBITORS:
• TACRINE- central inhibitor
• DONEZEPIL(Aricept) – not hepatotoxic, selective inhibitor
• RIVASTIGMINE (Excelon)
• GALANTHAMINE (Reminyl)
• For mild to moderate Alzheimer’s disease
![Page 91: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/91.jpg)
TACRINE
• Tetrahydroaminoacridine, THA
• Long acting anticholinesterase & muscarinic modulator
• Orally active
• Duration of action: 6-8 hrs
• Blocks both acetylcholinesterase & butyrylcholinesterase
• Inhibitory effects on M1, M2 & muscarinic cholinoceptors
![Page 92: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/92.jpg)
• Increases the release of acetylcholine from cholinergic nerve endings
• Inhibit MAO
• Decrease the release of GABA
• Increase the release of NE, dopamine, serotonin from nerve endings
![Page 93: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/93.jpg)
DONAZEPIL, RIVASTIGMINE, GALANTAMINE• Newer cholinesterase inhibitors with
adequate penetration to the CNS
• Indirect cholinomimetic effects than tacrine
![Page 94: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/94.jpg)
ADVERSE EFFECTS:
• Nausea and vomiting
• Hepatotoxicity is increased with tacrine
• Should be used with caution: ketoconazole, quinidine
![Page 95: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/95.jpg)
NEURONAL NICOTINIC RECEPTORS (NNRs)
![Page 96: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/96.jpg)
TARGACEPT
• Neuronal nicotinic receptors (NNRs), serve as key regulators of nervous system function.
• When the natural neurotransmitter acetylcholine, or a drug that mimics acetylcholine, binds to an NNR, the NNR normalizes chemical signaling, allowing neurons to communicate properly (neuromodulation)
• ."
![Page 97: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/97.jpg)
• results in increased signaling when the nervous system is understimulated and decreased signaling when the nervous system is overstimulated
• nervous system's "volume knob
![Page 98: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/98.jpg)
![Page 99: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/99.jpg)
NMDA GLUTAMATE RECEPTOR INHIBITORS
![Page 100: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/100.jpg)
MEMANTINE (Ebixa)
• Binds to NMDA receptor channels
• Produces a noncompetitive blockade
• Prevents the effect of excess glutamate leaking out from the damaged brain cells
• Treatment of moderate to severe form of Alzheimer’s disease
![Page 101: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/101.jpg)
TREATMENT:
INHIBITING NEURODEGENERATION
• Anti-inflammatory drugs– Ibuprofen, indomethacin
• Metal chelating agent– Clioquinol
![Page 102: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/102.jpg)
![Page 103: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/103.jpg)
POST –TEST:
1. Tacrine
2. Targacept
3. Rivastigmine
4. Memantadine
5. Donazepil
A. NMDA glutamate receptor inhibitor
B. Neuronal Nicotinic Receptors
C. Cholinesterase inhbitor
![Page 104: Antiparkinsons](https://reader035.vdocuments.net/reader035/viewer/2022062513/55782e46d8b42a9b438b5038/html5/thumbnails/104.jpg)
6. SELEGILINE
7. TOLCAPONE
8. ROPINOROLE
9. BENSERASIDE
10. BIPERIDEN
A. MAOI
B. COMT INHIBITOR
C. DOPAMINE AGONIST
D. ACH BLOCKING AGENT
E. DOPA DECARB INHIBITOR